← FDA DRUG APPROVALS

FDA ANDA · ANDA091358

OXALIPLATIN

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA091358
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-07
LATEST ACTION
2024-11-21
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription, Discontinued

Products

OXALIPLATINPrescription
OXALIPLATIN 100MG/20ML (5MG/ML) · INJECTABLE · INTRAVENOUS
OXALIPLATINDiscontinued
OXALIPLATIN 200MG/40ML (5MG/ML) · INJECTABLE · INTRAVENOUS
OXALIPLATINPrescription
OXALIPLATIN 50MG/10ML (5MG/ML) · INJECTABLE · INTRAVENOUS

Approval history

2024-11-21Labeling · Supplement 12 · standardAP
2022-03-08Labeling · Supplement 9 · standardAP
2017-11-14OriginalAP
2015-09-10Labeling · Supplement 2 · standardAP
2012-08-07OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →